AAC Accepts, published online ahead of print on 19 October 2009

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Held, J. Articles by Mordmüller, B. PubMed PubMed Citation Articles by Held, J. Articles by Mordmüller, B.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01090-09
Copyright (c) 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

In vitro activity of mirincamycin (U24729A) in Plasmodium falciparum isolates from Gabon

Jana Held, Richard Westerman, Peter G. Kremsner, and Benjamin Mordmüller^*

Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon; 1603 Evanston, Kalamazoo, MI, 49008, USA

^* To whom correspondence should be addressed. Email: benjamin.mordmueller{at}uni-tuebingen.de.

We assessed the in vitro activity of mirincamycin, a lincosamide antibiotic, against Plasmodium falciparum clinical isolates from Gabon. Growth was determined by HRP2-ELISA using an adapted protocol with prolonged incubation time (6 days) to account for antibiotic induced delayed death. Mirincamycin's cis and trans isomers are more active (median IC50: 3.2 nM and 2.6 nM) than the comparator drugs clindamycin (IC50: 12 nM) and doxycycline (IC50: 720 nM) and therefore further clinical development is promising.